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Introduction: Epidemiological studies report a 60e70% reduced risk of Parkinson's disease (PD) in
smokers as compared to non-smokers. However, relationships between former smoking and PD have
been poorly investigated.
Methods: We recruited 116 de novo PD subjects, and investigated current, former and never smoking,
and reasons for smoking cessation among former smokers. Two hundred and thirty-two controls were
matched by Propensity Score.
Results: PD subjects and controls were found to be current smokers (7.7 vs. 39.6%), former smokers (43.9
vs. 6.5%) and never smokers (48.2 vs. 53.9%). Logistic regression showed that current smokers were less
likely to have PD (p < 0.001; OR: 0.22; 95% CI: 0.10e0.46), while former smokers were more likely to have
PD (p < 0.001; OR: 7.6; 95% CI: 4.09e15.75), as compared to never smokers. Fifty-one PD patients re-
ported quitting smoking before PD diagnosis (mean time since cessation 9.4 ± 7.3 years). Most important
reasons to quit smoking in PD group were illness different from PD (26 subjects, 51.0%), knowledge of the
harmful effects of smoking (24 subjects, 47.0%), and physician's advice (1 subject, 2.0%).
Conclusion: The reduced prevalence of current smokers among PD subjects as compared to healthy
controls is consistent with previous ﬁndings, suggesting a possible neuroprotective effect of smoking.
However, it could be due, at least in part, to the increased prevalence of former smokers among PD
patients, that were more prone to quit smoking as compared to healthy controls. We suggest that
smoking cessation could be an early preclinical condition occurring in PD.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Parkinson's disease (PD) presents different possible de-
terminants, and environmental factors such as lifestyle-related
factors, seem to play a signiﬁcant etiologic role [1]. Among
different possible environmental factors, cigarette smoking hasbeen widely studied. In particular, several epidemiological studies
reported a 60e70% reduced risk of PD in smokers, when compared
to non-smokers [1e4]. Apparently, this association is dose-
dependent with reduced PD risk in relation to intensity and dura-
tion of smoking [4e6]. Furthermore, a positive effect of smoking on
motor features has been reported with a delayed time to disability
requiring dopaminergic therapy [7], and on non-motor symptoms
(NMS), with an improvement of smell in PD [8].
Association between quitting smoking and PD is an intriguing
matter, that has been poorly investigated so far. We may assume
Table 1
Demographics and clinical features of PD subjects and controls.
PD subjects (n ¼ 116) Controls (n ¼ 232) p-value
Gender
Male (%) 69 (59.5) 138 (59.5) 0.945
Female (%) 47 (40.5) 95 (40.5)
Age ± SD (range) 59.4 ± 8.4 (40e74) 58.7 ± 7.5 (40e72) 0.789
UPRDR part III 15.2 ± 7.1
NMSQuest total score 4.2 ± 3.2
p-values from c2, t-test or ManneWhitney test, as appropriate.
PD: Parkinson's disease; SD: standard deviation; UPDRS: uniﬁed Parkinson's disease
rating scale; NMSQuest: non-motor symptom questionnaire.
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changes occurring in PD [9], or causative as one of the factors
increasing the risk of developing PD over time. Large epidemio-
logical surveys grouped former with current smokers, missing a
separate analysis [2,10,11]. Some other studies suggested an overall
reduced risk of PD for former smokers, lower than never smokers
but higher than current ones [1,2,4], but the rate of former smokers
is reported to be extremely variable among PD subjects, ranging
from 15% up to 50% [5,12]. Interestingly, a recent study suggested
that patients with PD are able to quit smoking more easily than
controls and, thus, proposed that ease of smoking cessation is an
aspect of premanifest PD [13].
The aims of our study are: 1) to assess the prevalence of current,
former and never smokers between newly diagnosed and drug
naïve PD subjects, and healthy controls; 2) to describe reasons for
quitting smoking in PD, that have never been previously reported;
3) to evaluate the relationship between smoking status and motor
and non-motor features of PD.
2. Materials and methods
2.1. Study design
Our study was designed to evaluate differences in smoking habits between de
novo PD subjects and healthy controls. Secondary endpoints were describing rea-
sons for quitting smoking, and evaluating possible relationships between smoking
status and motor and non-motor symptoms of PD. The study was performed ac-
cording to the good clinical practice guidelines and the Declaration of Helsinki.
2.2. PD subjects
We enrolled de novo, drug-naïve patients with parkinsonism who were
consecutively referred to the Centre for PD and Movement Disorders at the
Department of Neurosciences at the University ‘‘Federico II’’ of Naples, Italy, within
2008 and 2009. The local ethical committee approved the study and all subjects
provided written informed consent. Inclusion criteria were: presence of a parkin-
sonian syndrome according to the United Kingdom Parkinson's Disease Society
Brain Bank Diagnostic Criteria [14,15]; onset less than 2 years before; no previous or
current treatment with dopaminergic drugs. Additional criteria for inclusion were
lack of signiﬁcant cerebral lesions on MRI or CT. Exclusion criteria were: diagnosis of
secondary (such as vascular and drug-induced) or familial parkinsonism, diagnosis
of atypical parkinsonism, namely, multiple system atrophy, progressive supra-
nuclear palsy, corticobasal syndrome, and dementia with Lewy bodies, according to
current diagnostic criteria [16e20]. Parkinsonism was diagnosed by movement-
disorder specialists experienced in parkinsonian disorders. All subjects were eval-
uated after 2 years in order to exclude subjects with symptoms and/or signs of
atypical parkinsonism, as previously reported [16e20].
Demographics and clinical data were recorded. An expert physician evaluated
motor features bymeans of Uniﬁed Parkinson's Disease Rating Scale (UPDRS) part III.
In addition, all patients completed the NMS Questionnaire (NMSQ), a validated tool
for detection of NMS [21]. The NMSQ consists of 30 questions with dichotomous
(yes/no) answers and of a total score, which ranges between 0 and 30, with higher
scores reﬂecting more NMS [21]. None of the patients was treated with anti-
parkinsonian drugs, anticholinergic agents, choline esterase inhibitors, antidepres-
sants, anxiolytic drugs, or other centrally acting substances that might have affected
both motor and non-motor evaluation.
Smoking habits were recorded (smoking duration and intensity), and PD sub-
jects were categorized according to self-reported smoking status as never, former, or
current smoker [22]. In particular, current smokers were deﬁned as those who had
smoked 100 or more cigarettes in their lifetime and were smokers when the survey
took place. Former smokers were those who reported as being smokers during their
lifetime but currently did not smoke. In addition, ever smokers PD patients were
asked about their age at starting and the number of cigarettes smoked per day.
Moreover, former smokers were asked to report the age at quitting and the most
important reason that led them to quit. For ever smokers (current and former
smokers), we calculated pack-years, as previously suggested (packs of cigarettes per
day multiplied by years smoked) [22]. Reasons to quit were categorized as previ-
ously suggested in similar surveys conducted in Italy [22e24]: illness and current
health-related conditions (different from PD); physician's advice; knowledge of the
harmful effects of smoking; pregnancy/birth of a child; economic reasons (cigarettes
too expensive); pressure to quit by partner/relatives; other reasons.
2.3. Controls
Controls were recruited at the Occupational Medicine Unit of the same hospital
within the same period. Concomitant diseases and treatments were recorded. All
controls underwent physical examination according to clinical practice. Smokinghabits were recorded, and controls were categorized according to participant self-
report smoking status as never, former, or current smoker, as previously reported
[22e24]. Since, unfortunately, reasons for quitting smoking were not assessed in our
control group, an Italian survey on a large population presenting similar age range
and geographical distribution was used for comparison with PD group [24].
2.4. Statistical analysis
First of all, PD subjects were matched to controls extracted from database of the
Occupational Medicine Unit considering covariates (age and gender), by using the
Propensity Score Matching (PSM), with a case/control matching ratio of 1/2. De-
mographic differences between groups were evaluated by c2, t-test or Man-
neWhitney test, as appropriate. Comparisons between PD subjects and controls in
relation to smoking status were conducted by a preliminary c2 test and by logistic
regression analysis with odds ratio and 95% conﬁdence intervals calculation. In order
to study other possible factors interfering with smoking status, the latter model was
corrected for age and gender. Subsequently, an additional categorization was per-
formed and a logistic regression model analyzed difference in prevalence of ever
smokers (former þ current smokers) and never smokers between PD subjects and
controls.
In order to examine secondary endpoints, a descriptive analysis was performed
with different reasons to quit smoking in PD group. Differences in pack-years be-
tween current and former smokers have been analyzed by t-test and analysis of
variance (ANOVA) corrected for age and gender. Furthermore, motor symptoms
were evaluated by regression analysis studying the relationship between UPDRS
part III and smoking status. In order to evaluate the quantitative relationship be-
tween smoking and motor symptoms in ever smokers (current and former), we
performed a regression model considering pack-years and UPDRS part III. Among
former smokers, time from cessation was related to UPDRS part III by regression
analysis. With regard to non-motor symptoms, NMSQ total score was related to
smoking status by regression analysis, and NSMQ single items were related to
smoking status by c2 test or Fisher's exact test, as appropriate. Subsequently, Bon-
ferroni correction for multiple comparisons was performed. In order to evaluate the
quantitative relationship between smoking and NMS in ever smokers (current and
former), we performed a regression model considering pack-years and NMSQ total
score. Among former smokers, time from cessation was related to NMSQ total score
by regression analysis.
Stata 12.0 and Microsoft Excel 2011 software were used for data processing and
statistical analysis. Results were considered statistically signiﬁcant for p < 0.05.3. Results
We recruited 116 PD subjects that were matched to 232 healthy
controls by PSM. No differences were found between cases and
controls for age and gender (Table 1).
PD subjects and controls were found to be current smokers (7.7
vs. 39.6%), former smokers (43.9 vs. 6.5%) and never smokers (48.2
vs. 53.9%) (Table 2; Fig. 1). With regard to our primary endpoint, c2
test showed an association between PD diagnosis and smoking
status (p < 0.001). In particular, at logistic regression analysis cur-
rent smoking was less likely associated to PD diagnosis (p < 0.001),
while smoking cessationwas more likely associated to PD diagnosis
(p < 0.001) (Table 2; Fig. 1). Age and gender did not appear to in-
ﬂuence smoking status differences between PD subjects and con-
trols (p ¼ 0.708 and p ¼ 0.366, respectively). Logistic regression
failed to show any association between ever smoking (current and
former) and PD diagnosis (p ¼ 0.324), since there was no difference
in prevalence of ever smokers and never smokers between PD
subjects and controls.
Table 2
Smoking status of PD subjects and controls. Results are shown from logistic regression analysis before and after correction for age and gender.
PD subjects (n ¼ 116) Controls (n ¼ 232) Unadjusted model Adjusted model
OR 95% CI p-value OR 95% CI p-value
Lower Upper Lower Upper
Smoking status
Never (%) 56 (48.2) 125 (53.9)
Current (%) 9 (7.7) 92 (39.6) 0.22 0.10 0.46 <0.001 0.23 0.11 0.48 <0.001
From years ± SD (range) 32.2 ± 11.6 (10e40)
Cigarettes per day ± SD (range) 14.6 ± 9.9 (5e40)
Pack-years 21.4 ± 15.7 (7.5e60)
Former (%) 51 (43.9) 15 (6.5) 7.6 3.39 14.63 <0.001 8.03 4.09 15.75 <0.001
From years ± SD (range) 9.4 ± 7.3 (0.5e21)
Pack-years 12.5 ± 9.5 (2e50)
Covariates
Age 0.78 0.46 1.33 0.708
Gender 1.00 0.97 1.04 0.366
PD: Parkinson's disease; OR: odds ration; 95% CI: 95% conﬁdence interval; SD: standard deviation.
M. Moccia et al. / Parkinsonism and Related Disorders 21 (2015) 216e220218Fifty-one PD patients reported quitting smoking before PD
diagnosis (mean time since cessation 9.4 ± 7.3 years, range 0.5e21).
In PD patients, most important reasons to quit smokingwere illness
and current health-related conditions (different from PD) (26
subjects, 51.0%), knowledge of the harmful effects of smoking (24
subjects, 47.0%), and physician's advice (1 subject, 2.0%). In a gen-
eral population sample from Southern of Italy [24], the most
important reasons to quit smoking were illness and current health-
related conditions (41.1%), knowledge of the harmful effects of
smoking (32.3%), and pregnancy (6.1%).
In PD subjects, smoking intensity evaluated by means of pack-
years, resulted to be signiﬁcantly higher in current smokers when
compared to former ones at t-test (p¼ 0.036) and ANOVA corrected
for age and gender (p ¼ 0.002).
Clinical features are shown in Table 1. Regression analysis failed
to show any association between UPDRS part III and smoking sta-
tus, considering never, former and current smokers. There was no
quantitative relationship between pack-year and UPDRS part III
(p ¼ 0.815) among ever smokers (current and former). Time from
cessation did not relate to UPDRS part III in former smokers
(p ¼ 0.164).
NMSQ total score did not relate to smoking status (p ¼ 0.357).
For NMSQ single item evaluation, in consideration of small sampleFig. 1. Bar chart showing differences in smoking status between PD subjects and
healthy controls. p-value from c2 test is shown.size and zero values for some items, Fisher's exact test was per-
formed and showed former smokers frequently reporting dribbling
saliva (p ¼ 0.044), while current and former smokers frequently
reporting difﬁculty concentrating or staying focused (p ¼ 0.021),
and difﬁculties in having sex (p ¼ 0.032) (Table 3). However, these
results were no longer signiﬁcant after correction for multiple
comparisons. A quantitative relationship was found between pack-
year among ever smokers (current and former) and NMSQ total
score, with subjects smokingmore pack-year presenting more NMS
(p ¼ 0.042; coefﬁcient: 0.08; 95% CI: 0.03e0.15). Time from cessa-
tion did not relate to NMSQ total score in former smokers
(p ¼ 0.991).
4. Discussion
This is the ﬁrst study evaluating smoking habits among newly
diagnosed and drug naïve PD subjects in relation to healthy con-
trols, recruited and categorized with highly selective criteria.
Considering our primary endpoint (difference in smoking status
between PD subjects and controls), the reduced prevalence of
current smokers among PD subjects is in line with previous studies
investigating similar outcomes, but the evaluation of de novo un-
treated PD subjects signiﬁcantly strengthens our ﬁndings. From this
view, we found that different smoking habits are present since
early phases of PD and, thus, they are not a consequence of PD
diagnosis, progression or treatment. In fact, concomitant health
problems can strongly modify smoking habits among general
population and, thus, previous studies evaluating treated or
advanced PD patients, could have been biased by PD diagnosis orTable 3
NMSQ single items related to smoking status.
NMSQ items p-values
Dribbling saliva during the day time: No Yes 0.044
Never smokers 47 7
Current smokers 9 0
Former smokers 35 14
Difﬁculty concentrating or staying focused: No Yes 0.021
Never smokers 50 4
Current smokers 6 3
Former smokers 37 12
Finding it difﬁcult to have sex when you try: No Yes 0.032
Never smokers 52 4
Current smokers 6 3
Former smokers 40 9
p-values from Fisher's exact test are reported.
NMSQ: non-motor symptom questionnaire.
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explanation for the reduced prevalence of smokers in PD is a
neuroprotective effect of smoking, that has been investigated in
several studies suggesting different mechanisms [25,26]. In
particular, substances contained in cigarette smoking may interact
with MAO-B in dopaminergic neurons possibly reducing oxidative
stress [25]. In addition, nicotine modulates dopamine release, with
a possible overall functional protective effect against nigrostriatal
degeneration [25]. Furthermore, genetic polymorphisms of MAO-B
and glutathione S-transferase (GST) may variably interact with
cigarette smoking, modifying the risk of PD [27]. More recently,
cigarette smoking has been suggested to change the composition of
the gut microbiota with reduced misfolding of alpha-synuclein in
enteric nerves and decreased propagation of the protein aggregates
to the central nervous system [28].
Interestingly, our study did not only show a decreased preva-
lence of current smokers, but also an increased prevalence of
former smokers among PD subjects when compared to controls.
Notably, in a large longitudinal study, Chen and colleagues found
that PD subjects are more likely than controls to quit smoking
earlier and the earliest they quitted smoking, the highest was the
risk of developing PD [12]. In addition, among almost 300 PD
subjects described by Kandinov and colleagues, former smokers
represents over 90% of ever smokers, conﬁrming that smoking
cessation frequently happens among PD subjects [6]. However,
both studies considered only two subgroups (never and ever
smokers) thus, missing a full analysis. In particular, at least in our
PD population, current and former smokers appeared to be
signiﬁcantly different for overall smoking exposure and, so,
deserved to be separately considered. By analyzing the prevalence
of the three different subgroups (never, former and current
smokers) in PD patients as compared to healthy controls, we could
hypothesize that the reduced prevalence of current smokers among
PD subjects could be attributed, at least in part, to the increased
prevalence of former smokers. The latter is supported by the fact
that prevalence of ever smokers (former and current smokers
evaluated together) is not different between our PD subjects and
controls. In this view, we may hypothesize that those who quit
smoking are more prone to develop PD, or alternatively pre-
symptomatic PD subjects are more prone to quit smoking. It is
interesting that a recent study supports the latter hypothesis,
suggesting that ease of smoking cessation could be considered a
premotor feature of PD [13]. In particular, in a large population Ritz
and colleagues found that subjects easily quitting smoking pre-
sented an increased risk of developing PD, and, more in general,
that PD patients were less likely to become habitual smokers [13].
In addition, they found that subjects with greater difﬁculty quitting
(and more prone to use nicotine substitutes) were less likely to
develop PD [13]. This is in line with the possibility that quitting
cigarettes might be a marker for PD onset, rather than smoking
itself having a neuroprotective effect. Anyway, in both cases
smoking cessation could be considered a condition that predates
the onset of PD.
Interestingly, the average period since former smokers quitted
smoking is around 10 years, so that their smoking cessation could
possibly date during 1 or 2 Braak stage of PD timeline [29]. Those
stages are characterized by sympathetic nervous system changes
and, thus, quitting smoking could represent a way of restoring
sympathetic-parasympathetic balance by reducing the nicotinic
receptor-mediated parasympathetic stimulation. Alternatively,
reduced sensation seeking due to mesocorticolimbic dopaminergic
system degeneration may lead to a suppression of linked behaviors
(i.e. smoking) in a prodromal phase of PD [9]. Both hypotheses are
of course speculative, but our ﬁndings represent an initial clue for
further investigations.With regard to our secondary endpoints, this is the ﬁrst study
reporting reasons for quitting smoking among PD subjects. In
particular, we found that health and knowledge of the harmful
effects of smoking are the main reasons that led PD subjects to quit
smoking. Comparing our PD subjects to a large Italian population
screened with the same questionnaire for smoking cessation rea-
sons, it seems that PD subjects are apparently more sensitive to the
harmful consequences of smoking and, thus, possibly more prone
to quit smoking. We recognize that this is a preliminary result and
that comparing our PD subjects to the general population might
have been biased by differences in age and gender distribution.
Therefore, further studies in different countries should be per-
formed to conﬁrm our results and to be trans-culturally reliable.
However, it has already been reported that PD subjects tend to be
more passive, more introspective, less likely to take risks, and more
self-controlled, and in turn may choose not to smoke or to quit
smoking [6,9].
When evaluating motor features of PD, we failed to ﬁnd re-
lationships between UPDRS part III and smoking status or pack/
year. This is possibly due to the reduced sample size and to the lack
of longitudinal motor data, not allowing clearly assessing the efﬁ-
cacy of smoking on motor symptoms [7]. However, it has been
suggested that smoking possibly does not have a neuroprotective
effect in patients already diagnosed with PD [30]. It has to be re-
ported that early differences in personality, leading to variable
smoking habits, could be associated with subsequent development
of different PD motor phenotypes. Unfortunately, we did not found
this difference in our PD population due to the reduced sample size
with a low rate of akinetic-rigid subjects (data not shown) [1,31].
An additional secondary endpoint of the present study is the
evaluation of the relationship between non-motor symptoms of PD
and smoking status. Interestingly, the intensity of smoking posi-
tively related to NMSQ total score in both current and former
smokers. In addition, our pilot study seems to suggest that PD
subjects complaining daytime dribbling were more frequently
former smokers and that PD subjects complaining more difﬁculties
in having sex, a well-known side effect of cigarette smoking, were
more frequently current and former smokers. While increased
dribbling may have been involved in the decision of quitting
smoking in order to reduce additional stimuli to salivation, it is
difﬁcult to explain the increased difﬁculties in concentrating
among former smokers. Unfortunately, due to small sample size,
these results were no longer signiﬁcant after multiple test correc-
tion, and thus have to be considered very preliminary.
We must acknowledge some limitations. First of all, we did not
perform any genetic analysis in our subjects, even though it has
been suggested that one or more susceptibility genes act as a
background to the effect of smoking [11]. Furthermore, there are
limits in the clinical diagnosis of PD and, therefore, we cannot
exclude some contamination in our population due to other causes
of parkinsonian features. In addition, information on smoking was
based on self-reports and, consequently, recall bias may exist.
Moreover, we did not assess passive smoking in both cases and
controls [10].
In conclusion, the present study broadens our knowledge on the
relationship between smoking and PD. In line with previous
studies, we found a reduced prevalence of current smokers among
PD subjects, supporting a possible neuroprotective efﬁcacy of
smoking. In addition, we showed that smoking cessation is a
frequent behavior in preclinical PD, and may represent an early
non-motor condition occurring in PD and preceding PD diagnosis
up to 10 years. Moreover, we presented for the ﬁrst time reasons for
quitting smoking in PD and possible relationships between smok-
ing and NMS of PD. Present results strongly encourage additional
studies to evaluate the reasons for different smoking habits in PD.
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